Compound 17392

A new oral pharmaceutical drug for type- two diabetes had been approved for clinical use, it was called Compound 17392. Marketing companies instantly wanted to have prescribers adopt and sell the product and researchers wanted to further investigate previous reports of liver toxicity in patients. Now since paying patients to try new pharmaceutical drugs was an issue due to it appearing to interfere with clinical judgement and upholding the duty to do what is best for the patient, a new idea of furthering research for the drug came into play. The idea included recruiting a group of physicians who were in the top ten percent of prescribers for type-two diabetes. Following regulations put in place by researchers, these physicians were to enter eligible patients into the trial for Compound

They were to report on patients’ side effects, patients use of the drug, and both patient and physician subjective evaluations. Physicians who were interested in participating in this research would be paid three hundred dollars for ever patient they entered into the study, as well as an additional three hundred for the patients who participated in a one year follow up evaluation. The payment in this case was considered compensation for physician’s time and effort. An endocrinologist who practiced in New York City, Dr. Carlos Carera, was invited to attend the two-day protocol meeting to introduce the phase four clinical trial. He was interested in the development and research since some of his patients either could not tolerate or weren’t doing well on the available drugs for diabetes. Dr. Carera’s goal seems to involve participating in research to evolve and improve drugs for type-two diabetes and to be able to benefit his patients. Yet if he agrees to participate in the trial, does the fact that he’s